Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children

Journal of Autoimmunity

Volumn 9, Issue 6, 1996, Pages 739-745

  Carel, Jean Claude ^a,d   Boitard, Christian ^b   Eisenbarth, George ^c   Bach, Jean François ^b   Bougnères, Pierre François ^a  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Barbara Davis Center   (United States)

^d HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

diabetes prevention; immunosuppression; insulin secretion; prediabetes

Indexed keywords

AUTOANTIBODY; CYCLOSPORIN A; HLA DR ANTIGEN; INSULIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE TOLERANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE DIABETES MELLITUS; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

EID: 0030445613     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0096     Document Type: Article

References (43)

1. 1. Stiller C.R., Dupre J., Gent M., Jenner M.R., Keown P.A., Laupacis A., Martell R., Rodger N.W., von Graffenried B., Wolfe B.M.J. 1984. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362-1367
2. 2. Feutren G., Papoz L., Assan R., Vialettes B., Karsenty G., Vexiau P., Du Rostu H., Rodier M., Sirmai J., Lallemand A., Bach J-F. 1986. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2: 119-124
3. 3. Bougneres P.F., Carel J.-C., Castano L., Boitard C., Gardin J.P., Landais P., Hors J., Mihatsch M.J., Paillard M., Chaussain J.-L., Bach J.F. 1988. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N. Engl. J. Med. 318: 663-670
4. 4. The Canadian-European randomized control trial group. 1988. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37: 1574-1582
5. 5. Bougneres P.F., Landais P., Boisson C., Carel J.-C., Frament N., Boitard C., Chaussain J.-L., Bach J.F. 1990. Limited duration of the remissions of insulin dependency in children with recent overt type I diabetes treated with low dose cyclosporine. Diabetes 39: 1264-1272
6. 6. De Filippo G., Carel J.-C., Landais P., Bach J.-F., Boitard C., Bougneres P.F. 1996. Long term results of early cyclosporine therapy in juvenile type 1 insulin dependent diabetes. Diabetes 45: 101-104
7. 7. Bach J.-F. 1994. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev. 15: 516-542
8. 8. Maclaren N.K. 1988. Perspectives in diabetes. How, when and why to predict IDDM. Diabetes 37: 1591-1594
9. 9. Thai A.C., Eisenbarth G.S. 1993. Natural history of IDDM. Diabetes Reviews 1: 1-14
10. 10. Riley W.J., Maclaren N.K., Krishner J., Spillar R.P., Silverstein J.H., Schatz D.A., Schwartz S., Malone J., Shah S., Vadheim C., Rotter J.I. 1990. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N. Engl. J. Med. 323: 1167-1172
11. 11. Krischer J.P., Schatz D., Riley W.J., Spillar R.P., Silverstein J.H., Schwartz S., Malone J., Shah S., Vadheim C.M., Rotter J.I., Quattrin T., Maclaren N.K. 1993. Insulin and islet cell autoantibodies as time-dependent covariates in the development of insulin-dependent diabetes: a prospective study in relatives. J. Clin. Endocrinol. Metab. 77: 743-749
12. 12. Bleich D., Jackson R.A., Soeldner J.S., Eisenbarth G.S. 1990. Analysis of metabolic progression to type I diabetes in ICA+ relatives of patients with type I diabetes. Diabetes Care 13: 111-118
13. 13. Ginsberg-Fellner F., Dobersen M.J., Witt M.E., Rayfield E.J., Rubinstein P., Notkins A.L. 1982. HLA antigens, cytoplasmic islet cell antibodies, and carbohydrate tolerance in families of children with insulin-dependent diabetes mellitus. Diabetes 31: 292-298
14. 14. Srikanta S., Ganda O.P., Gleason R.E., Jackson R.A., Soeldner J.S., Eisenbarth G.S. 1984. Pre-type I diabetes: linear loss of beta-cell response to intravenous glucose. Diabetes 33: 717-720
15. 15. Chase H.P., Garg S.K., Butler-Simon N., Klingensmith G., Norris L., Ruskey C.T., O'Brien D. 1991. Prediction of the course of pre type 1 diabetes. J. Pediatr. 118: 838-841
16. 16. Feutren G., Mihatsch M.J. The International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. 1992. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N. Engl. J. Med. 326: 1654-1660
17. 17. Elliott R.B., Chase H.P. 1991. Prevention or delay of type I (insulin dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34: 362-365
18. 18. Dumont Herskowitz R., Jackson R.A., Soeldner J.S., Eisenbarth G.S. 1991. Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. J. Autoimmun. 2: 733-737
19. 19. Keller R.J., Eisenbarth G.S., Jackson R.A. 1993. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341: 927-928
20. 20. Carel J.-C., Boitard C., Bougneres P.F. 1993. Decreased insulin response to glucose in islet cell antibody negative siblings of type 1 diabetic children. J. Clin. Invest. 92: 509-513
21. 21. National Diabetes Data Group. 1979. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057
22. 22. Ziegler A.G., Dumont Herskowitz R., Jackson R.A., Soeldner J.S., Eisenbarth G.S. 1990. Predicting type I diabetes. Diabetes Care 13: 762-775
23. 23. Thivolet C., Beaufrere B., Geburher L., Chatelain P., Orgiazzi J., Francois R. 1991. Autoantibodies and genetic factors associated with the development of type I (insulin-dependent) diabetes mellitus in first degree relatives of diabetic patients. Diabetologia 34: 186-191
24. 24. Boitard C., Bonifacio E., Botazzo G.F., Gleichmann H., Molenaar J. 1988. Immunology and Diabetes Workshop: report on the third international (stage 3) workshop on the standardisation of cytoplasmic islet cell antibodies. Diabetologia 31: 451-452
25. 25. Castano L., Boitard C., Bougneres P.F. 1988. Cyclosporin A suppresses insulin autoantibodies and heterologous insulin antibodies in type I diabetic children. Diabetes 37: 1048-1052
26. 26. Vardi P., Dib S.A., Tuttleman M., Connely J.E., Gribergs M., Radizabeh A., Riley W.J., Maclaren N.K., Eisenbarth G.S., Soeldner J.S. 1987. Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type I diabetes mellitus. Diabetes 36: 1286-1291
27. 27. Gonzalez R., Michael A. 1987. The urinary system: glomerular filtration. In Nelson Textbook of Pediatrics. Behrman R.E. and Vaughan V.C, eds. W.B. Saunders, Philadelphia, 1111-1114
28. 28. Eisenbarth G.S. 1986. Type I diabetes mellitus: a chronic autoimmune disease. N. Engl. J. Med. 314: 1360-1368
29. 29. Dupre J., Jenner M.R., Mahon J.L., Purdon C., Rodger N.W., Stiller C.R. 1991. Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine. Diabetes 40: 598-604
30. 30. Gepts W., In't Veld P.A. 1987. Islet morphologic changes. Diab. Metab. Rev. 3: 859-872
31. 31. Itoh N., Hanafusa T., Miyazaki A., Miyagawa J., Yamagata K., Yamamoto K., Waguri M., Imagawa A., Tamura S., Inada M., Kawata S., Tarui S., Kono N., Matsuzawa Y. 1993. Mononuclear cell infiltration and its relatijon to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92: 2313-2322
32. 32. Hänninen A., Jalkanen S., Salmi M., Toikkanen S., Nikolakaros G., Simell O. 1992. Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J. Clin. Invest. 90: 1901-1910
33. 33. Strandell E., Eizirik D.L., Sandler S. 1990. Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus. J. Clin. Invest. 85: 1944-1950
34. 34. Maki T., Ichikawa T., Blanco R., Porter J. 1992. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc. Natl. Acad. Sci. USA 89: 3434-3438
35. 35. Chatenoud L., Thervet E., Primo J., Bach J.F. 1994. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA 91: 123-127
36. 36. Sempe P., Bedossa P., Richard M.F., Villa M.C., Bach J.F., Boitard C. 1991. Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice. Eur. J. Immunol. 21: 1163-1169
37. 37. Korsgren O., Jansson L. 1994. Characterization of mixed syngeneic-allogenic and syngeneic-xenogenic islet-graft rejections in mice. Evidence of functional impairment of the remaining syngeneic islets in xenograft rejections. J. Clin. Invest. 93: 1113-1119
38. 38. Nerup J., Mandrup-Poulsen T., Molvig J. 1987. The HLA-IDDM association: implications for etiology and pathogenesis of IDDM. Diab. Metab. Rev. 3: 779-802
39. 39. Eizirik D.L., Sandler S., Palmer J.P. 1993. Repair of pancreatic beta-cells. A relevant phenomenon in early IDDM? Diabetes 42: 1383-1391
40. 40. Inman L.R., McAllister C.T., Chen L., Hughes S., Newgard C.B., Kettman J.R., Unger R.H., Johnson J.H. 1993. Autoantibodies to the GLUT-2 glucose transporter of beta cells in insulin-dependent diabetes mellitus of recent onset. Proc. Natl. Acad. Sci. USA 90: 1281-1284
41. 41. Rakotoambinina B., Timsit J., Deschamps I., Laborde K., Boitard C., Assan R., Robert J.J. 1995. Cyclosporin A does not delay insulin dependency in asymptomatic type 1 diabetic patients. Diabetes Care 18: 1487-1490
42. 42. Bennett Johnson S., Tercyak K.P. 1995. Psychological impact of islet cell antibody screening for IDDM on children, adults, and their family members. Diabetes Care 18: 1370-1372
43. 43. Eisenbarth G.S., Verge C.F., Allen H., Rewers M.J. 1993. Perspective in diabetes: the design of trials for prevention of IDDM., Diabetes 42: 941-947.